natgillin/translations-raw huggingface dataset:
In the second study, patients taking Revolade were around 8 times more likely than those taking placebo to reach the target platelet count of between 50,000 and 400,000 per microlitre during the 6 months of treatment. 
V drugi študiji je bila pri bolnikih, ki so jemali zdravilo Revolade, verjetnost, da dosežejo ciljno število trombocitov med 50 000 in 400 000 na mikroliter v šestih mesecih zdravljenja, približno osemkrat večja kot pri skupini, ki je jemala placebo.
In children with ITP, the most common side effects include nose and throat infection, cough, fever, pain in the belly or in the mouth and throat, toothache and runny nose. 
Pri otrocih z imunsko trombocitopenično purpuro so najpogostejši neželeni učinki okužbe nosu in grla, kašelj, povišana telesna temperatura, bolečina v trebuhu ali v ustih in žrelu, zobobol in izcedek iz nosu.
• thrombocytopenia in adults with chronic (long-term) hepatitis C, a liver disease caused by the hepatitis C virus. 
• trombocitopenije pri odraslih s kroničnim (dolgotrajnim) hepatitisom C, tj. boleznijo jeter, ki jo povzroča okužba z virusom hepatitisa C. Zdravilo Revolade se uporablja, kadar je trombocitopenija prehuda, da bi dovoljevala zdravljenje z interferonom (vrsto zdravljenja hepatitisa C);
This increases the production of platelets, improving platelet counts. 
Zato začne nastajati več trombocitov, kar poveča njihovo raven.
if you are more than 3 months pregnant. 
če ste noseči več kot 3 mesece.
In some cases you may have to stop taking one of the medicines. 
V nekaterih primerih boste morda morali nehati jemati eno od teh zdravil.
Date of first authorisation: 16 January 2007 Date of latest renewal: 21 November 2011 
Datum prve odobritve: 16. januar 2007 Datum zadnjega podaljšanja: 21. november 2011
Elderly (age 65 years or over) 
Starejši (starost 65 let in več)
It is preferable to take your medicine at the same time each day. 
Zaželeno je, da vzamete zdravilo vsak dan ob istem času.
If you forget to take this medicine, take it as soon as you remember. 
Če ste pozabili vzeti zdravilo, ga vzemite, takoj ko se spomnite.
Your doctor may need to change your dose and/or to take other precautions. 
Zdravnik vam bo morda moral spremeniti odmerek in/ali upoštevati druge previdnostne ukrepe.
• Shock (including cardiogenic shock). 
• Šok (vključno s kardiogenim šokom).
if you are taking any of the following medicines used to treat high blood pressure: 
če jemljete katero od naslednjih zdravil, ki se uporabljajo za zdravljenje visokega krvnega tlaka:
Do not exceed the prescribed dose. 
Ne prekoračite predpisanega odmerka.
D-90429 Nuremberg Germany 
D-90429 Nürnberg Nemčija
Then take your next dose at its usual time. 
Naslednji odmerek nato vzemite ob običajnem času.
So, if you are not sure how this medicine will affect you, do not drive, use machinery, or do other activities that you need to concentrate on. 
Če niste prepričani, kako bo to zdravilo vplivalo na vas, ne upravljajte vozil, ne uporabljajte orodja ali strojev in ne izvajajte drugih dejavnosti, ki zahtevajo koncentracijo.
This can affect how well you can concentrate. 
Vpliva lahko na vašo sposobnost koncentracije.
(It is also better to avoid Dafiro in early pregnancy, see Pregnancy section). 
(Zdravilu Dafiro se je bolje izogibati tudi v zgodnji nosečnosti, glejte poglavje Nosečnost).
Stevens-Johnson syndrome 
Stevens-Johnson sindrom -
Rare (may affect up to 1 in 1,000 people): Confusion. 
Redki (pojavijo se pri do 1 od 1.000 ljudi): zmedenost.
In two long-term follow-up studies the effect of Dafiro was maintained for over one year. 
V dveh dolgoročnih spremljevalnih študijah se je učinek zdravila Dafiro ohranil več kot eno leto.
if you have severe low blood pressure (hypotension). 
če imate zelo znižan krvni tlak (hipotenzijo).
A total of 33,357 hypertensive patients aged 55 or older were randomised and followed for a mean of 4.9 years. 
Skupno so randomizirali 33.357 hipertenzivnih bolnikov, starih 55 let ali več, in jih spremljali povprečno 4,9 leta.
Novartis Farmacéutica SA Ronda de Santa Maria 158 08210 Barberà del Vallès, Barcelona Spain 
Novartis Farmacéutica SA Ronda de Santa Maria 158 08210 Barberà del Vallès, Barcelona Španija
- Swelling of the tongue and throat which causes great difficulty breathing. 
- otekanje jezika in grla, ki zelo oteži dihanje.
If any of these cause you problems or if they last for more than one week, you should contact your doctor. 
Če vam katerikoli od teh povzroča težave ali traja dlje kot 1 teden, pokličite svojega zdravnika.
However, if it is almost time for your next dose, skip the dose you missed. 
Če pa je že skoraj čas za naslednji odmerek, preskočite izpuščeni odmerek.
Age, gender, race or body mass index (≥30 kg/m 2, <30 kg/m 2) did not influence the response to 
Starost, spol, rasa ali indeks telesne mase (≥30 kg/m 2, <30 kg/m 2) niso vplivali na odziv na zdravilo
The proportion of the maternal dose received by the infant has been estimated with an interquartile range of 3-7%, with a maximum of 15%. 
Ocenjujejo, da je delež materinega odmerka, ki ga prejme otrok, v interkvartilnem razponu 3-7 %, najvišji delež pa je 15 %.
Approximate size: diameter 8.20 mm. 
Približna velikost: premer 8,20 mm.
There were only modest signs of maternal toxicity (moderate reduction of body weight) in this study. 
Znaki toksičnih učinkov pri materi (zmerno zmanjšanje telesne mase) so bili v tej študiji le skromni.
See also information under the heading “Do not take Dafiro”. 
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Dafiro”.
Both of these substances help to control high blood pressure. 
Obe pomagata obvladovati visok krvni tlak.
Paediatric population (age below 18 years) No pharmacokinetic data are available in the paediatric population. 
Pediatrična populacija (starost do 18 let) Farmakokinetičnih podatkov za pediatrično populacijo ni.
Your doctor may also check your kidney function. 
Zdravnik bo morda pregledal tudi delovanje vaših ledvic.
• Second and third trimesters of pregnancy (see sections 4.4 and 4.6). 
• Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinkuzdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
The antihypertensive effect of a single dose of the combination persisted for 24 hours. 
Antihipertenzivni učinek enega odmerka kombinacije je trajal 24 ur.
Depending on how you respond to the treatment, your doctor may suggest a higher or lower dose. 
Glede na vaš odziv na zdravilo vam bo zdravnik nato morda svetoval večji ali manjši odmerek.
Do not use this medicine after the expiry date which is stated on the carton and blister. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in pretisnem omotu.
Dafiro and older people (age 65 years or over) Your doctor should exercise caution when increasing your dose. 
Zdravilo Dafiro in starejši ljudje (stari 65 let ali več) Zdravnik mora biti pri zviševanju vašega odmerka previden.
• Severe hypotension. 
• Huda hipotenzija.
Approximate size: 14.2 mm (length) x 5.7 mm (width). 
Približna velikost: 14,2 mm (dolžina) x 5,7 mm (širina).
Dafiro with food and drink 
Zdravilo Dafiro skupaj s hrano in pijačo
Valsartan is highly bound to serum proteins (94-97%), mainly serum albumin. 
Valsartan je močno vezan na beljakovine v serumu (94-97 %), predvsem na albumin v serumu.
Elimination: Valsartan shows multiexponential decay kinetics (t½α <1 h and t½ß about 9 h). 
Izločanje: Valsartan kaže multieksponentno kinetiko upadanja (t½α <1 uro in t½ß približno 9 ur).
Follow your doctor's instructions for the starting dose carefully. 
Natančno se držite zdravnikovih navodil glede začetnega odmerka.
Your doctor will normally advise you to stop taking Dafiro before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Dafiro. 
Zdravnik vam bo praviloma svetoval, da prenehate z jemanjem zdravila Dafiro še preden zanosite oziroma takoj, ko ugotovite da ste noseči in vam bo svetoval jemanje drugega zdravila namesto zdravila Dafiro.
It is recommended to take Dafiro with some water. 
Zdravilo Dafiro je priporočljivo vzeti z malo vode.
Mean systemic AUC of valsartan is higher by 70% in the elderly than in the young therefore caution is required when increasing the dosage. 
Povprečna sistemska AUC valsartana je pri starejših za 70 % večja kot pri mladih, zato je pri večanju odmerka potrebna previdnost.
In double-blind, controlled clinical trials, the incidence of peripheral oedema by dose was as follows: 
V dvojno slepih, kontroliranih kliničnih preskušanjih je bila incidenca perifernih edemov glede na odmerke sledeča:
Dafiro is not recommended in early pregnancy (first 3 months), and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. 
Jemanje zdravila Dafiro v zgodnjem obdobju nosečnosti (v prvih 3 mesecih) ni priporočljivo, če pa ste noseči več kot 3 mesece, ga ne smete jemati, ker lahko uporaba po tretjem mesecu nosečnosti povzroči resno škodo vašemu otroku.
Use in patients with hypertension 
Uporaba pri bolnikih s hipertenzijo
Valsartan is primarily eliminated in faeces (about 83% of dose) and urine (about 13% of dose), mainly as unchanged drug. 
Valsartan se v prvi vrsti izloči v blato (okrog 83 % odmerka) in urinu (okrog 13 % odmerka), v glavnem v obliki nespremenjenega zdravila.
The safety of Dafiro has been evaluated in five controlled clinical studies with 5,175 patients, 2,613 of whom received valsartan in combination with amlodipine. 
Varnost zdravila Dafiro so ocenjevali v petih kontroliranih kliničnih študijah s 5.175 bolniki, od katerih jih je 2.613 prejemalo valsartan v kombinaciji z amlodipinom.
if you have a condition affecting the renal glands called “primary hyperaldosteronism”. 
če imate posebno bolezen nadledvičnih žlez, imenovano “primarni hiperaldosteronizem”.
- Swelling of eyelids, face or lips. 
- otekanje očesnih vek, obraza ali ustnic.
Patients taking Dafiro and driving vehicles or using machines should take into account that dizziness or weariness may occasionally occur. 
Bolniki, ki jemljejo zdravilo Dafiro in vozijo motorna vozila ali uporabljajo stroje, morajo upoštevati, da se lahko občasno pojavi omotica ali utrujenost.
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data). 
Neželeni učinki so razvrščeni po oznakah pogostnosti upoštevaje naslednji dogovor: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) 
Dvojno zaviranje sistema renin-angiotenzin-aldosteron (RAAS)
Do not take Dafiro if you are allergic to amlodipine or to any other calcium channel blockers. 
Ne jemljite zdravila Dafiro če ste alergični na amlodipin ali na katerikoli zaviralec kalcijevih kanalčkov.
Amlodipine (mg) 
amlodipin (mg)
Amlodipine can have mild or moderate influence on the ability to drive and use machines. 
Amlodipin ima lahko blag do zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Concomitant use not recommended 
Sočasna uporaba ni priporočena
Children and adolescents The use of Dafiro in children and adolescents is not recommended (aged below 18 years old). 
Otroci in mladostniki Zdravila Dafiro ni priporočljivo uporabljati pri otrocih in mladostnikih (starih manj kot 18 let).
Amlodipine/Valsartan 
Amlodipin/valsartan
• Obligation to conduct post-authorisation measures The MAH shall complete, within the stated timeframe, the below measures: 
• Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet Imetnik dovoljenja za promet z zdravilom mora v določenem časovnem okviru izvesti naslednje ukrepe:
What Dafiro is and what it is used for 
Kaj je zdravilo Dafiro in za kaj ga uporabljamo
Marked and potentially prolonged systemic hypotension up to and including shock with fatal outcome have been reported. 
Poročali so o izraziti in potencialno dolgotrajni sistemski hipotenziji vse do šoka, tudi takšnega s smrtnim izidom.
Patients with hepatic impairment have decreased clearance of amlodipine with resulting increase of approximately 40-60% in AUC. 
Bolniki z okvaro jeter imajo znižan očistek amlodipina; posledica je zvišanje AUC za približno 40-60 %.
The safety and efficacy of amlodipine in hypertensive crisis have not been established. 
Varnost in učinkovitost amlodipina pri hipertenzivni krizi nista bili ugotovljeni.
Interactions linked to amlodipine 
Interakcije, povezane z amlodipinom
Do not stop taking your medicine unless your doctor tells you to. 
Ne prenehajte jemati zdravila, če vam ni tako naročil zdravnik.
During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2-4 weeks and is sustained during long-term therapy. 
Med večkratno uporabo je največje znižanje krvnega tlaka pri vseh odmerkih praviloma doseženo v 2 do 4 tednih in se med dolgotrajnim zdravljenjem ohrani.
In elderly patients, caution is required when increasing the dosage. 
Pri starejših bolnikih je treba odmerjanje povečevati previdno.
Valsartan is mostly eliminated unchanged via the bile. 
Valsartan se večinoma izloči nespremenjen v žolču.
The combination of these substances has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone. 
Kombinacija teh dveh učinkovin ima aditiven antihipertenziven učinek in znižuje krvni tlak v večji meri kot vsaka sestavina zase.
if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body). 
če imate zoženje aortne zaklopke (aortno stenozo) ali kardiogeni šok (stanje, v katerem srce ne more črpati dovolj močno, da bi oskrbelo telo s krvjo).
As a result, the blood vessels relax and blood pressure is lowered. 
Zato se žile sprostijo in krvni tlak se zniža.
This may involve itching, reddening of the skin or difficulty in breathing. 
To lahko vključuje srbenje, rdečino kože ali oteženo dihanje.
Interactions linked to valsartan 
Interakcije, povezane z valsartanom
if you have liver or kidney problems. 
če imate težave z jetri ali ledvicami.
an ACE inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. 
zaviralec ACE (na primer enalapril, lizinopril ali ramipril), zlasti če imate kakšne težave z ledvicami, ki so povezane s sladkorno boleznijo.
The safety and efficacy of Dafiro in children aged below 18 years have not been established. 
Varnost in učinkovitost zdravila Dafiro pri otrocih, starih manj kot 18 let, nista bili dokazani.
The following side effects have been reported. 
Poročali so o naslednjih neželenih učinkih.
As with all other vasodilators, special caution is indicated in patients suffering from mitral stenosis or significant aortic stenosis that is not high grade. 
Tako kot pri vseh vazodilatatorjih, je posebna previdnost potrebna pri bolnikih z mitralno stenozo ali s pomembno aortno stenozo, ki sicer ni močno izražena.
To date there is no experience of the safe use of Dafiro in patients who have had a recent kidney transplantation. 
Doslej ni izkušenj glede varnosti uporabe zdravila Dafiro pri bolnikih, ki jim je bila nedavno presajena ledvica.
Evaluation of patients with heart failure or post-myocardial infarction should always include assessment of renal function. 
Pregled bolnikov, ki imajo srčno popuščanje ali so v obdobju po miokardnem infarktu, mora vedno vključevati oceno ledvične funkcije.
Elimination: Amlodipine elimination from plasma is biphasic, with a terminal elimination half-life of approximately 30 to 50 hours. 
Izločanje: Eliminacija amlodipina iz plazme je dvofazna s terminalnim razpolovnim časom eliminacije približno 30 do 50 ur.
In marmosets at comparable doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy including raised blood urea nitrogen and creatinine. 
Pri marmozetkah so bile pri primerljivih odmerkih spremembe podobne, vendar bolj resne, še zlasti na ledvicah, kjer je prišlo do razvoja nefropatije, med drugim do zvišanja vrednosti dušika sečnine in kreatinina v krvi.
Stopping your treatment with Dafiro may cause your disease to get worse. 
Če prenehate jemati zdravilo Dafiro, se lahko vaša bolezen poslabša.
if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. 
če imate sladkorno bolezen ali okvarjeno delovanje ledvic in in se zdravite z zdravilom za zniževanje krvnega tlaka, ki vsebuje aliskiren.
Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000-fold) greater affinity for the AT1 receptor than for the AT2 receptor. 
Valsartan nima delnega agonističnega učinka na receptorjih AT1, njegova afiniteta za receptorje AT1 pa je veliko (približno 20.000-krat) večja kot za receptorje AT2.
Valsartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. 
Valsartan se ne veže oz. ne zavira drugih hormonskih receptorjev ali ionskih kanalčkov, pomembnih za srčno-žilno regulacijo.
The usual dose of Dafiro is one tablet per day. 
Običajni odmerek zdravila Dafiro je ena tableta na dan.
Abrupt withdrawal of Dafiro has not been associated with a rapid increase in blood pressure. 
Nenadna prekinitev zdravila Dafiro ni povezana s hitrim zvišanjem krvnega tlaka.
- Heart attack, abnormal heart beat. 
- srčni napad, nenormalen srčni utrip.
Other possible side effects of Dafiro: 
Drugi možni neželeni učinki zdravila Dafiro:
if you have had heart failure or have experienced a heart attack. 
če ste kdaj imeli srčno popuščanje ali ste preživeli srčni infarkt.
Other medicines and Dafiro 
Druga zdravila in zdravilo Dafiro
For convenience, patients receiving valsartan and amlodipine from separate tablets/capsules may be switched to Dafiro containing the same component doses. 
Zaradi praktičnosti je možno bolnike, ki dobivajo valsartan in amlodipin v ločenih tabletah/kapsulah, prevesti na zdravilo Dafiro, ki vsebuje enaka odmerka sestavin.
Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. 
Poleg tega lahko sočasna uporaba antagonistov angiotenzina II in NSAIDs poveča tveganje za poslabšanje delovanja ledvic ter povečanje kalija v serumu.
if you suffer from heart failure after a heart attack. 
če imate srčno popuščanje po srčnem infarktu.
The recommended dose of Dafiro is one tablet per day. 
Priporočeni odmerek zdravila Dafiro je ena tableta na dan.
The effect of amlodipine on infants is unknown. 
Učinek amlodipina na dojene otroke ni znan.
Some of these patients previously experienced angioedema with other medicinal products, including ACE inhibitors. 
Pri nekaterih od teh bolnikov je do angioedema prišlo že prej pri jemanju drugih zdravil; med drugim pri jemanju zaviralcev ACE.
Placebo-controlled trials 
S placebom kontrolirana preskušanja
If a diurectic is also used, the risk of lithium toxicity may presumably be increased further with Dafiro. 
Če je uporabljen tudi diuretik, uporaba zdravila Dafiro predvidoma poveča toksične učinke litija.
If you have taken too many tablets of Dafiro, or if someone else has taken your tablets, consult a doctor immediately. 
Če ste vzeli večji odmerek zdravila Dafiro, kot bi smeli Če ste vzeli preveč tablet zdravila Dafiro, ali je vaše tablete vzel kdo drug, se takoj posvetujte z zdravnikom.
The increased plasma levels of angiotensin II following AT1 receptor blockade with valsartan may stimulate the unblocked receptor subtype AT2, which appears to counterbalance the effect of the AT1 receptor. 
Zvišana koncentracija angiotenzina II po zavrtju receptorjev AT1 z valsartanom lahko stimulira nezavrte receptorje podvrste AT2, ki, kot kaže, izravnavajo učinek receptorjev AT1.
Valsartan does not inhibit ACE, also known as kininase II, which converts angiotensin I to angiotensin II and degrades bradykinin. 
Valsartan ne zavira ACE (znane tudi kot kininaza II), ki pretvarja angiotenzin I v angiotenzin II in razgrajuje bradikinin.
If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. 
Če se pri bolnikih, ki jemljejo amlodipin, pojavlja omotica, glavobol, utrujenost ali navzea, je njihova zmožnost reagiranja lahko zmanjšana.
No drug-drug interaction studies have been performed with Dafiro and other medicinal products. 
Študij medsebojnega delovanja z zdravilom Dafiro in drugimi zdravili niso izvedli.
Pack sizes: 56, 98 or 280 film-coated tablets. 
Velikosti pakiranj: 56, 98 ali 280 filmsko obloženih tablet.
If you think you may be allergic, talk to your doctor before taking Dafiro. 
Če domnevate, da bi lahko bili alergični, se posvetujte z zdravnikom, preden vzamete zdravilo Dafiro.
• Haemodynamically unstable heart failure after acute myocardial infarction. 
• Hemodinamično nestabilno srčno popuščanje po akutnem miokardnem infarktu.
Do not take Dafiro with grapefruit or grapefruit juice. 
Zdravila Dafiro ne zaužijte skupaj z grenivko ali z grenivkinim sokom.
Co-administration of inhibitors of the uptake transporter (rifampicin, ciclosporin) or efflux transporter (ritonavir) may increase the systemic exposure to valsartan. 
Sočasna uporaba zaviralcev privzemnega prenašalca (rifampicina, ciklosporina) ali zaviralcev izlivnega prenašalca (ritonavirja) lahko poveča sistemsko izpostavljenost valsartanu.
Caution should be exercised in patients with liver disease (see section 4.2). 
Previdnost je potrebna pri bolnikih z boleznijo jeter (glejte poglavje 4.2).
if you have had a kidney transplant or if you had been told that you have a narrowing of your kidney arteries. 
če so vam presadili ledvico ali vam povedali, da imate zožitev ledvičnih arterij.
if you are allergic to valsartan or any of the other ingredients of Dafiro this medicine (listed in section 6). 
če ste alergični na valsartan ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
if your doctor has told you that you have a narrowing of the valves in your heart (called “aortic or mitral stenosis”) or that the thickness of your heart muscle is abnormally increased (called “obstructive hypertrophic cardiomyopathy”). 
če vam je zdravnik povedal, da imate zožene srčne zaklopke (t.i. aortno ali mitralno stenozo) ali nenormalno zadebeljeno srčno mišico (t.i. obstruktivno hipertrofično kardiomiopatijo).
A few patients have experienced these serious side effects (may affect up to 1 in 1,000 people). 
Nekateri neželeni učinki so lahko resni in zahtevajo takojšnjo zdravniško obravnavo: Te resne neželene učinke je imelo nekaj bolnikov (pojavijo se lahko pri do 1 od 1.000 ljudi).
Amlodipine has been studied in patients with chronic stable angina, vasospastic angina and angiographically documented coronary artery disease. 
Amlodipin je raziskan pri bolnikih s kronično stabilno angino pektoris, vazospastično angino pektoris in angiografsko potrjeno boleznijo koronarnih arterij.
Interactions common to the combination 
Interakcije pogoste ob kombinaciji
Dafiro is available in packs containing 7, 14, 28, 30, 56, 90, 98 or 280 tablets and in multipacks comprising 4 cartons, each containing 70 tablets, or 20 cartons, each containing 14 tablets. 
Zdravilo Dafiro je na voljo v pakiranjih, ki vsebujejo 7, 14, 28, 30, 56, 90, 98 ali 280 tablet in v skupnih pakiranjih s 4 škatlami, od katerih vsaka vsebuje 70 tablet, ali z 20 škatlami, od katerih vsaka vsebuje 14 tablet.